Advanced Oncotherapy (AVO) – Sinophi update

Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that it has come to an agreement with Sinophi Healthcare Limited to terminate the purchase orders announced on 25 March 2015 and 21 October 2015. In addition, both parties have reached an agreement to terminate the distribution agreement also announced […]

Beaufort Securities view on Advanced Oncotherapy (AVO)

Beaufort Securities view on Advanced Oncotherapy (AVO). It always comes as a surprise when the market reacts violently to some news item whose impact was considered already to be priced-in. Yesterday’s announcement told shareholders nothing new. Back in November, AVO detailed the fact that Sinophi was no longer to proceed with the installation of LIGHT […]

Advanced Oncotherapy (AVO) – Appointment of Non-Executive Directors

  Advanced Oncotherapy (AVO), the developer of next-generation proton therapy systems for cancer treatment, announces the appointment of Professor Steve Myers OBE and Mr Hans von Celsing as Non-Executive Directors with immediate effect. In addition, Mr von Celsing will become Senior Independent Non-Executive Director. Professor Myers’ appointment follows the announcement of the Company’s intention to […]

Advanced Oncotherapy (AVO) – Sinophi Update

Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment announces that on 23 January 2017, the Company was informed by Sinophi Healthcare Limited (“Sinophi”) that it wished to terminate the purchase orders announced on 25 March 2015 and 21 October 2015. Advanced Oncotherapy is firmly of the view that Sinophi has no […]

Advanced Oncotherapy (AVO) Non-dilutive financing plan update

Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that, in September 2016, it commenced discussions concerning a proposal it had received from a potential strategic partner that involves, inter alia, non-dilutive financing arrangements, which were mentioned in the announcement of 30 September 2016. Discussions with this potential partner are […]

Doctors warn over cancer op cancellations amid NHS “pressure” – BBC

Senior doctors say they are concerned about the number of cancer patients having their operations cancelled amid “tremendous pressure” facing the NHS in England this winter. Ian Eardley, from the Royal College of Surgeons, said a shortage of beds was one of the causes. Such surgery is usually protected under treatment time guidelines, he added. […]

Proton beam therapy used in tumour treatment in UAE – The National UAE

An advanced form of radiotherapy that reduces the risk of side effects in cancer patients will be available in the UAE for the first time when a Dh220 million health centre opens in Abu Dhabi in 2018. Proton beam therapy, which uses protons rather than X-rays, is regarded as a safer way to treat hard-to-reach […]

Advanced Oncotherapy (AVO) – Additional Director Dealing

Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that Dr Enrico Vanni, a Non-Executive Director of the Company, purchased 25,000 ordinary shares of 25 pence each in the Company at a price of 87 pence per Ordinary Share. Following this transaction, Dr Vanni now holds 823,946 Ordinary Shares representing […]